PCV21

BIOLOGICAL3 trials

Sponsors

Sanofi Pasteur, a Sanofi Company, Sanofi, Vaxcyte, Inc.

Conditions

Pneumococcal InfectionsPneumococcal VaccinesSickle Cell Disease

Phase 3

Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

Active, not recruitingNCT06838000

Sanofi Pasteur, a Sanofi CompanyPneumococcal Infections

Start: 2025-02-28End: 2026-12-01Updated: 2025-10-06

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

RecruitingNCT07247188

SanofiSickle Cell Disease

Start: 2026-01-20End: 2027-01-07Target: 100Updated: 2026-01-28

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Active, not recruitingNCT07284654

Vaxcyte, Inc.Pneumococcal Vaccines

Start: 2025-12-01End: 2027-01-01Updated: 2026-03-31